The Michael J. Fox Foundation awarded X-tosis a $2.74 million grant to advance XTS-001 toward clinical development for Parkinson’s disease. The funding will support confirmatory studies, biomarker development, and IND-enabling work for the lead program from X-tosis’s Mitoxts platform, which is designed to target mitochondrial dysfunction underlying neurodegeneration.